NIKKEI 225
37,073.66 -1,006.04 (-2.64%) HANG SENG
16,151.29 -234.58 (-1.43%) CRUDE OIL
84.51 +1.78 (+2.15%) GOLD FUTURES
2,404.30 +6.30 (+0.26%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,720.11 -202.66 (-0.41%)
Novo Nordisk A/S (NVO)
After hours:
- Investor's Business Daily
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
- Investor's Business Daily
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
